Want to see SE:DVYSR full AI Analyst Report?
Top Page
Devyser Diagnostics AB
(DVYSR)
Select Model
Select Model
Rating:57Neutral
Price Target:
kr57.00
▼(-3.23% Downside)
Action:Reiterated
Date:10/28/26
The score is primarily supported by improving financial performance (return to profitability, strong margins, and low leverage). It is held back by mixed technicals (negative MACD and below longer-term moving averages) and a high P/E valuation with no dividend yield data to offset the premium.
Positive Factors
Profitability inflection
The return to positive earnings alongside strong gross and operating margins indicates a meaningful improvement in the economics of the business. If maintained, this profitability provides greater capacity to fund product development, commercial expansion, and operations without relying as heavily on external capital.
Negative Factors
Revenue contraction
A declining revenue base limits the durability of the current earnings improvement because margin gains cannot compound indefinitely without renewed demand. Continued contraction could weaken scale benefits, constrain commercial investment, and make future growth more dependent on further efficiency gains.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability inflection
The return to positive earnings alongside strong gross and operating margins indicates a meaningful improvement in the economics of the business. If maintained, this profitability provides greater capacity to fund product development, commercial expansion, and operations without relying as heavily on external capital.
Read all positive factors
Devyser Diagnostics AB (DVYSR) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr928.94M
Dividend YieldN/A
Average Volume (3M)21.86K
Price to Earnings (P/E)59.8
Beta (1Y)0.55
Revenue Growth6.51%
EPS GrowthN/A
CountrySE
Employees110
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.92
Shares Outstanding16,889,807
10 Day Avg. Volume22,683
30 Day Avg. Volume21,857
Financial Highlights & Ratios
PEG Ratio2.59
Price to Book (P/B)5.35
Price to Sales (P/S)7.56
P/FCF Ratio282.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.7
Revenue Forecast (FY)kr245.93M
Devyser Diagnostics AB Business Overview & Revenue Model
Company Description
Headquartered in Hägersten, Sweden, and established in 2004, Devyser Diagnostics AB (publ) specializes in the development, manufacturing, and global sale of advanced diagnostic kits and solutions for DNA testing. The company's innovative products ...
How the Company Makes Money
Devyser Diagnostics makes money primarily by selling molecular diagnostic products to clinical laboratories and other healthcare testing providers. Key revenue streams include: (1) sales of diagnostic assay kits (reagents/consumables) used to run ...
Devyser Diagnostics AB Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 250.40M | 250.50M | 216.90M | 169.30M | 126.61M | 93.48M |
| Gross Profit | 195.80M | 201.90M | 172.70M | 148.10M | 105.77M | 74.66M |
| EBITDA | 53.50M | 37.70M | -26.40M | -43.80M | -46.02M | -18.05M |
| Net Income | 15.30M | -8.40M | -61.50M | -53.60M | -45.95M | -20.73M |
Balance Sheet | ||||||
| Total Assets | 493.10M | 469.70M | 473.80M | 510.10M | 500.63M | 456.87M |
| Cash, Cash Equivalents and Short-Term Investments | 81.00M | 77.50M | 144.50M | 262.90M | 363.60M | 377.64M |
| Total Debt | 45.80M | 51.90M | 59.10M | 74.80M | 21.20M | 12.96M |
| Total Liabilities | 112.10M | 115.40M | 124.80M | 125.00M | 69.19M | 40.18M |
| Stockholders Equity | 381.00M | 354.30M | 349.10M | 385.10M | 431.44M | 416.68M |
Cash Flow | ||||||
| Free Cash Flow | 20.50M | 6.70M | -123.70M | -101.70M | -66.30M | -25.28M |
| Operating Cash Flow | 36.00M | 8.20M | -46.80M | -69.70M | -40.50M | -16.48M |
| Investing Cash Flow | -58.50M | -70.70M | -76.90M | -32.00M | -23.86M | -10.32M |
| Financing Cash Flow | 3.10M | -2.80M | 7.80M | -200.00K | 48.94M | 395.93M |
Devyser Diagnostics AB Technical Analysis
Neutral
58.90
Price Trends
54.45
Positive
61.99
Negative
76.70
Negative
Market Momentum
0.40
Negative
54.54
Neutral
77.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:DVYSR, the sentiment is Neutral. The current price of 58.9 is above the 20-day moving average (MA) of 52.22, above the 50-day MA of 54.45, and below the 200-day MA of 76.70, indicating a neutral trend. The MACD of 0.40 indicates Negative momentum. The RSI at 54.54 is Neutral, neither overbought nor oversold. The STOCH value of 77.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:DVYSR.
Devyser Diagnostics AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | kr928.94M | 59.78 | ― | ― | 6.51% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | kr371.09M | -28.83 | ― | ― | 54.37% | 52.22% | |
43 Neutral | kr33.70M | -0.30 | -279.07% | ― | 31.66% | 79.68% | |
43 Neutral | kr174.38M | -0.78 | -303.61% | ― | 51.21% | 42.24% | |
42 Neutral | kr74.32M | -0.20 | -229.18% | ― | 143.94% | 70.95% | |
40 Underperform | kr40.19M | -2.31 | -58.52% | 1.06% | -16.09% | 78.68% |
* General Sector Average
SE:DVYSR
Devyser Diagnostics AB
55.00
-68.00
-55.28%
SE:BOUL
Boule Diagnostics AB
1.04
-5.45
-84.03%
SE:IMMNOV
Immunovia AB
0.05
-0.27
-84.28%
SE:SCIB
SciBase Holding AB
12.35
-13.24
-51.74%
SE:PROGEN
Prostatype Genomics AB
0.11
-0.12
-52.86%
SE:CLBIO
Corline Biomedical AB
14.20
-5.75
-28.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.